JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takemori, A. E.
Right arrow Articles by Portoghese, P. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takemori, A. E.
Right arrow Articles by Portoghese, P. S.

Receptors for opioid peptides in the guinea-pig ileum

AE Takemori and PS Portoghese

Cryptic receptor sites in the guinea-pig ileum preparation have been uncovered by the treatment of the preparation with the highly selective, irreversible mu opioid receptor antagonist, beta- funaltrexamine. These beta-funaltrexamine-insensitive sites appear to interact only with opioid peptides ([D-Ala2, D-Leu5]enkephalin, [D- Ala2, Met5]enkephalinamide, Tyr-D-Ser-Gly-Phe-Leu-Thr and [D-Ala2, MePhe4, Gly-ol5]enkephalin) but not with nonpeptide agonists. These new sites could not be protected by either mu-selective (morphiceptin and [D-Ala2, MePhe4, Gly-ol5]enkephalin) or delta-selective ([D-Ala2, D- Leu5]enkephalin, Tyr-D-Ser-Gly-Phe-Leu-Thr, (Allyl)2-Tyr-Gly-Gly-psi- (CH2S)-Phe-Leu, and (Allyl)2-Tyr-Aib-Aib-Phe-Leu) peptides against beta- chlornaltrexamine alkylation. However, naloxone afforded full protection of these sites against beta-chlornaltrexamine alkylation. The delta-selective antagonist, (Allyl)2-Tyr-Aib-Aib-Phe-Leu, had no activity at these cryptic sites at concentrations that effectively blocked delta receptors in the mouse vas deferens. The cryptic sites do not appear to be typical mu or delta receptors. The new receptors were termed mu', a mu subtype, and a receptor model that is consonant with our data is presented.

Volume 235, Issue 2, pp. 389-392, 11/01/1985
Copyright © 1985 by American Society for Pharmacology and Experimental Therapeutics







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1985 by the American Society for Pharmacology and Experimental Therapeutics.